Rentschler Biopharma and Coriolis Pharma have announced a strategic collaboration to offer clients seamless, end-to-end solutions from early formulation through to commercial manufacturing.
The contract development and manufacturing organisation (CDMO) for biopharmaceuticals and the research and development organisation (CRDO) will combine their complementary expertise to accelerate the product’s path to market.
This collaboration responds to the evolving needs of the biologics market, as increasing complexity in modalities and regulatory expectations drive demand for integrated, science-driven solutions.
Clients will benefit from a unified interface and aligned project teams, reducing tech transfer risks and enabling faster progression from early development to clinical and commercial stages.
Coriolis Pharma brings a unique combination of in silico and wet lab formulation and drug product development expertise, scientific depth and advanced analytical capabilities to this collaboration.
With a legacy of scientific excellence and commitment to innovation, Coriolis supports every drug development phase from R&D to GMP.
The company’s collaborative approach and deep scientific expertise make it a trusted partner from discovery to commercial manufacturing and lifecycle management.
Rentschler Biopharma brings extensive experience in bioprocess development and manufacturing for multiple biotherapeutics, backed by a strong track record of reliability and quality.
With a long-standing commitment to client-centric solutions, the company provides robust support from process development through to commercial supply.
By focusing on technical excellence, long-term partnerships and tailored solutions, Rentschler Biopharma ensures successful outcomes at every stage of the project.
Benedikt von Braunmühl, CEO of Rentschler Biopharma, commented: “This marks an important step for both our organisations and for our global clients and their patients."
"Coriolis Pharma shares our focus on technical excellence, reliability, as well as our client-centric approach."
"By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster."
"This collaboration perfectly exemplifies our vision of advancing medicine to save lives, together.”
Silvia Steyrer-Gruber, CEO of Coriolis Pharma, added: “At Coriolis, we believe that scientific excellence, client-focused innovation and strong partnerships are key to advancing complex biopharmaceutical programmes efficiently and reliably."
"With Rentschler Biopharma, we have a trusted partner whose process development and manufacturing expertise ideally complements our deep understanding of formulation development and analytical services."
"This collaboration is a testament to our Coriolis partnering strategy, which fosters synergistic relationships across the biopharma ecosystem. Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success."
"Our teams look forward to working closely with Rentschler Biopharma on this collaboration.”
The integrated service offering will be available to clients starting December 2025.
Both organisations have operations in Germany and the US, providing global reach and local access for clients in key biopharmaceutical markets.